Windlas Biotech receives certificate of Good Manufacturing Practices from SAHPRA

Windlas Biotech Limited, one of the leading domestic pharmaceutical formulations contract development and manufacturing organization ("CDMO") industry in India, has received certificate of Good Manufacturing Practices (GMP) from SAHPRA (South African Health Products Regulatory Authority). The company had undergone the inspection audit from 20th to 29th September 2021.

Commenting on this Mr. Hitesh Windlass, Managing Director - Windlas Biotech said, "We are pleased to receive the GMP certificate from SAHPRA. With this the company can start manufacturing and sell its products in the fast-growing South Africa market.

Recently, the company concluded EU GMP inspection with zero critical observations and deficiencies. This we believe is a testimony of company's quality standards and capabilities. The company's growth trajectory is expected to accelerate further, in the upcoming quarters underpinned by the geographic expansion for CDMO and Exports Vertical driven by the positive regulatory audit outcomes".

Shares of Windlas Biotech Ltd was last trading in BSE at Rs. 236.25 as compared to the previous close of Rs. 236.80. The total number of shares traded during the day was 2100 in over 251 trades.

The stock hit an intraday high of Rs. 239.60 and intraday low of 235.25. The net turnover during the day was Rs. 497443.00.

Source : Equity Bulls

Keywords

WindlasBiotech CDMO GMPCertificate SAHPRA